Description
13,14-dihydro-15-keto-Prostaglandin E
2-d
9 (13,14-dihydro-15-keto PGE
2-d
9) is intended for use as an internal standard for the quantification of 13,14-dihydro-15-keto PGE
2 by GC- or LC-MS. 13,14-dihydro-15-keto PGE
2 is a metabolite of PGE
2 and the primary PGE
2 metabolite in plasma.
1,2 It is formed from PGE
2 via a 15-keto PGE
2 intermediate by 15-oxo-PG Δ
13 reductase.
2 Unlike PGE
2, 13,14-dihydro-15-keto PGE
2 does not bind effectively to the PGE
2 receptors EP
2 and EP
4 expressed in CHO cells (K
is = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC
50s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE
2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery.
3 Levels of 13,14-dihydro-15-keto PGE
2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).
4
References
1. Hamberg, M., and Samuelsson, B.
On the metabolism of prostaglandins E1 and E2 in man J. Biol. Chem. 246(22),6713-6721(1971).
2. Nishigaki, N., Negishi, M., and Ichikawa, A.
Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist Mol. Pharmacol. 50(4),1031-1037(1996).
3. Husslein, P., and Sinzinger, H.
Concentration of 13,14-dihydro-15-keto-prostaglandin E2 in the maternal peripheral plasma during labour of spontaneous onset Br. J. Obstet. Gynaecol. 91(3),228-231(1984).
4. Hughes, D., Otani, T., Yang, P., et al.
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer Cancer Prev. Res. (Phila.) 1(4),241-249(2008).
